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Abstract 
The advent of nanotechnology has reignited interest in the lungs as a major 
route of drug delivery for both systemic and local treatments.  The large 
surface area of the lungs and the minimal barriers impeding access to the 
lung periphery make this organ a suitable portal for a variety of therapeutic 
interventions.  Nanoparticles provide new formulation options for both 
dispersed liquid droplet dosage forms such as metered dose inhalers and 
nebulizers, and dry powder formulations.  Nanoparticle formulations have 
many advantages over traditional dosage forms, such as enhanced 
dissolution properties and the potential for intracellular drug delivery.  
Specifically, pure drug nanoparticles, polymeric nanoparticles, polyelectrolyte 
complexes, and drug-loaded liposomes offered some encouraging results for 
delivering drugs to and through the lungs.  Methods are being investigated to 
produce nanoparticles with properties suitable for improving access to the 
peripheral lung.  Techniques such as spray drying and supercritical fluid 
extraction have been employed to produce nanoparticle formulations for 
pulmonary delivery.  In Chapter 1, the benefits of nanoparticle formulations 
and current progress are compared in light of the practical encumbrances of 
producing formulations, and possible toxicological effects of these materials.  
In Chapter 2, a novel, nanoparticle-based insulin formulation is 
described for the treatment of diabetes.  Diabetes is a set of diseases 
characterized by defects in insulin utilization, either through autoimmune 
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destruction of insulin-producing cells (Type I) or insulin resistance (Type II).  
Treatment options can include regular injections of insulin, which can be 
painful and inconvenient, often leading to low patient compliance.  To 
overcome this problem, novel formulations of insulin are being investigated, 
such as inhaled aerosols.  Sufficient deposition of powder in the distal regions 
of the lung to maximize systemic absorption requires precise control over 
particle size and density, with particles between 1 and 5 µm in aerodynamic 
diameter being within the respirable range.  Insulin nanoparticles were 
produced by titrating insulin dissolved at low pH up to the pI of the native 
protein, and were then further processed into microparticles using solvent 
displacement.  Particle size, crystallinity, dissolution properties, structural 
stability, and bulk powder density were characterized.  The work described in 
Chapter 2 demonstrates that pure drug insulin microparticles can be 
produced from nanosuspensions with minimal processing steps and with 
suitable properties for deposition in the peripheral lung. 
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1. Nanoparticle Formulations in Pulmonary Drug Delivery 
The lungs are perhaps the most historic portal for drug delivery.  As early as 
1500 B.C.E., the ancient Egyptians inhaled vapors to treat a variety of 
diseases.1  Unfortunately, the lungs were soon forgotten as a major route of 
drug delivery, and it was not until the early 1950s that serious consideration of 
the lungs was resurrected with the invention of the first metered dose inhaler 
(MDI).  It was used to locally administer albuterol to treat asthma,1 and offered 
little precision in control of dosing.  Fortunately, this was not a major concern 
due to albuterol’s wide therapeutic window when used as an anti-asthmatic.2 
 Today, researchers have made great strides in the development of 
precise pulmonary drug delivery technologies, both in terms of inhaler design 
and advances in particle engineering.  Some of the most promising advances 
have manifested from applying nanotechnology to particle engineering.3  
These have led to several innovative systemic delivery formulations and new 
treatment paradigms.  Here, the benefits of nanoparticle formulations are 
presented in the context of how they relate to local and systemic pulmonary 
drug delivery.  In addition, specific formulation methods are presented to 
illustrate the many strategies available to engineer nanoparticles suitable for 
delivery to the peripheral lung. 
 
1.1. Pulmonary Physiology and Drug Absorption 
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The primary functions of the lungs are to enable gas exchange between the 
blood and the external environment, and to maintain homeostatic systemic pH.  
The respiratory system is composed of the trachea, which bifurcates into the 
bronchi.  The bronchi continue to branch into smaller bronchioles, and 
ultimately the terminal bronchi, which end with the alveolar sac.  The 
conducting airways are lined with ciliated columnar epithelium, which 
transition to a cuboidal shape approaching the distal airways.  The lumen of 
the bronchial airways is lined with a thin layer of serous fluid, upon which 
floats a layer of mucus, which helps to entrap aerosolized particles.  The 
coordinated, rhythmic beating of the cilia constantly moves this mucous layer 
toward the proximal airways, where it is either swallowed or expectorated 
(mucociliary clearance).  Particles settling in the peripheral lung have been 
reported to have a residence time of about 24 hours in a healthy adult 
patient.1 
The alveolar epithelial surface is primarily composed of type I 
pneumocytes, which share a basement membrane with the pulmonary 
capillaries.  The alveoli also contain type II pneumocytes, which secrete lung 
surfactant to prevent alveolar collapse, and macrophages, which are 
responsible for clearing large particles.  There are approximately 300 million 
alveoli in the lungs, with a combined surface area that is greater than 100 m2, 
and with an alveolar epithelium as thin as 0.1 µm.1,4  This large surface area, 
combined with an extremely thin barrier between the pulmonary lumen and 
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the capillaries, creates conditions that are well suited for efficient mass 
transfer.4 
Particle deposition in the lungs occurs by inertial impaction, 
sedimentation, or diffusion.  Particles larger than 10 µm in diameter are 
generally subject to inertial impaction in the oropharyngeal region, or 
sedimentation in the bronchial region, where delivered drug may be expected 
to have little systemic therapeutic effect.4-6  At the other extreme, particles 
with diameters substantially smaller than 1 µm are less likely to reach the 
alveolar region, but are not likely to deposit and thus are exhaled.  Particles 
with aerodynamic diameters between 1-5 µm will bypass deposition in the 
mouth and throat and efficiently deposit in the lung periphery.1,5-7 
Once deposited, drugs encounter a variety of physicochemical and 
biological barriers.  Inside the peripheral lung, particles must dissolve and 
drug must diffuse through the epithelial barrier and into the blood stream; 
however, larger particles that dissolve slowly are still subject to mucociliary 
clearance and phagocytosis by alveolar macrophages.  Penetration 
enhancers can sometimes be incorporated into pulmonary formulations to 
enhance systemic bioavailability, but the long-term safety of these 
compounds still needs to be evaluated.1  Molecules such as small peptides 
may be subject to enzymatic degradation in the lungs, although the 
environment is much more hospitable to proteins and nucleic acids than the 
gastrointestinal tract.  Additionally, as the molecular mass of a peptide 
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increases, its tertiary and quaternary structures become more complex, which 
reduces peptidase activity on the protein.1  In addition, cyclization of peptides 
can reduce susceptibility to degradation by peptidases.8  Finally, the transport 
of proteins tends to decrease as molecular weight increases, with proteins 
greater than 150 kDa having a difficult time accessing systemic circulation.  
Despite these encumbrances, pulmonary delivery may well represent the 
ideal route to deliver peptides and small protein therapeutics. 
The lungs are suitable for both local and systemic drug delivery.  There 
are many local diseases of the lung that are prime candidates for inhalation 
therapy, such as asthma, emphysema, chronic obstructive pulmonary disease 
(COPD), cystic fibrosis, primary pulmonary hypertension, and cancer.2  
Treating these diseases locally is advantageous since the drug avoids first-
pass metabolism and deposits directly at the disease site.  This type of 
application of the drug to the lung epithelium also eliminates potential side 
effects caused by the high systemic concentrations typical of conventional 
delivery methods, and can reduce costs because smaller doses can be 
used.2  The benefits of systemic drug delivery through the lungs include a 
rapid onset of action and an increased bioavailability over oral formulations, 
especially for peptide drugs.9,10  Several companies have capitalized on these 
perceived benefits to develop inhalable forms of insulin that have the potential 
to rapidly control postprandial hyperglycemia.11-13  Despite the lack of 
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commercial success of inhaled insulin thus far, much excitement surrounds 
the potential medicinal benefit of inhaled therapeutics. 
 
1.2. Types of Inhalers 
There are currently three major types of inhalers used for pulmonary drug 
delivery; nebulizers, metered dose inhalers (MDIs), and dry powder inhalers 
(DPIs).  All three types of devices use different delivery mechanisms, and 
hence require different types of drug formulations. 
Nebulizers represent an historic technology for delivering drugs to the 
lungs.  Air-jet nebulizers use compressed jets of high velocity air to shear a 
bulk suspension or solution into a liquid film at the spray nozzle.14  The film 
then collapses under surface tension,14 forming droplets that are aerosolized 
and inhaled by the patient.  Ultrasonic nebulizers utilize a vibrating 
piezoelectric crystal, which causes cavitation bubble formation at the surface 
of the solution or suspension.14  This generates a dense mist when droplets 
effervesce from the turbulent medium,14 which is inhaled by the patient.  
Nebulizers produce ultra fine droplets (~1 µm) with a high degree of 
polydispersity, and particles larger than the droplet size have been reported 
not to be aerosolized.14  For this reason, nebulizers may not be appropriate 
for delivering large particles to the lungs. 
 Metered dose inhalers are pressurized vessels that contain drug that is 
either dissolved or suspended in a liquid propellant (typically 
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hydrofluoroalkanes, or HFA).15  When actuated, the device releases a 
metered volume of drug and propellant through a valve system.16  Although 
dosing with MDIs is typically more reproducible than DPIs, metered dose 
inhalers are generally more difficult to use because they require coordination 
between actuation and inhalation in order to ensure optimal deposition of drug 
in the lungs.15,17  For this reason, patients and physicians sometimes need to 
undergo training in order to develop the proper technique.17  Another 
disadvantage of MDIs is their use of HFA propellants, which have been linked 
to global warming.15  MDIs also typically contain surface-active agents like 
surfactants, which may impact lung performance.15 
 Dry powder inhalers are breath-actuated devices that deliver a dry 
powder drug through shear-induced aerosolization.16  For this reason, the 
actual dose delivered from a DPI is highly dependent on the inspiratory flow 
rate, and can sometimes be difficult to replicate.15,17,18  Additionally, particles 
within a DPI tend to agglomerate due to electrostatic interactions and/or 
hygroscopic phenomena, thereby inhibiting aerosolization.  Despite these 
disadvantages, DPIs are generally easier to use than other types of inhalers 
since they do not require coordination of actuation and inhalation, and they do 
not use liquid propellants.15,19  There are three typical DPI device categories: 
the single-unit dose inhaler, the multi-dose reservoir inhalers, and multi-unit 
dose inhalers.20  Single-unit dose inhalers require the patient to load a gelatin 
capsule into the device before each use, which is broken upon actuation.  
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Multi-dose reservoir inhalers contain a bulk supply of drug in which individual 
doses are released with each actuation.20  This gating mechanism of action 
helps to minimize the flow-dependent dosing that occurs with other DPIs.  
Another variation of the reservoir inhaler is the multi-unit dose inhaler, which 
contains multiple sealed blisters that are individually broken upon actuation.20 
 In addition to the three major inhaler types, inhalers that utilize 
eletrohydrodynamic spray, or electrospray, are also being investigated.  In 
this mechanism, nebulization of the liquid droplets relies solely on electric 
charging and dispersion occurs due to the Coulombic forces between 
droplets.21  This technique has been shown to retain the structure of proteins, 
and has been considered as a method to deliver insulin to the lungs for the 
treatment of diabetes.21  Additionally, electrospray offers good control over 
droplet size distribution, being able to approach monodispersity.22,23  One 
drawback to electrospray is that highly conductive solutions, such as salt 
solutions, may be too conductive (and thus will not hold a charge) to reach 
the target droplet size.22 
 
1.3. Advantages of Nanoparticle Formulations in Pulmonary Drug 
Delivery 
In a 1959 lecture, Richard Feynman proposed that, in the future, small 
machines will be used to make smaller machines, and these in turn will be 
used to make even smaller machines, all the way down to the atomic level.24  
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Today, Professor Feynman’s vision has been partially realized with the 
advent of nanotechnology.  Advances in nanoscience have propelled 
innovations in a number of scientific disciplines, including medicine and 
pharmaceutical formulation.  Nanotechnology has the potential to 
revolutionize medicine, and has already presented new regulatory 
challenges.25,26  Innovations are occurring rapidly, as demonstrated by the 
exponential increase in nanotechnology-related pharmaceutical patents over 
the past 15 years.27 
 Drug nanoparticle formulations are usually created in one of two ways.  
Particles may be precipitated out of solution (bottom-up), or they are milled 
from larger particles (top-down).28  In both mechanisms, the total surface area 
increases, which increases the free energy of the particles.  The system 
compensates for this increase in free energy by dissolving crystalline nuclei 
and precipitating onto other particles in a process known as Ostwald 
Ripening,29 or by agglomerating smaller particles.  Generating stable 
nanoparticle colloids typically necessitates the use of surfactants, which 
decrease the surface tension at the particle surface and thereby help to 
reduce the increase in free energy.28 
 Nanoparticle pharmaceuticals offer several advantages over 
formulations containing larger particles.  For example, as the size of a particle 
decreases, a greater number of its molecules will be found at its surface 
rather than inside the particle,3 giving nanoparticles a large surface area to 
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volume ratio.6  This increase in total surface area leads to an increase in 
dissolution velocity, as described by the Noyes-Whitney equation.30  
Additionally, the saturation solubility of a particle increases as the particle size 
decreases, which is described by the Kelvin and Ostwald-Freundlich 
equation.30  Interestingly, this size-dependence only becomes apparent after 
the particle size falls below approximately 1 µm,30 making it entirely unique to 
nanoparticles.  These phenomena make nanoparticle formulations a highly 
effective means to enhance mass transfer from the particle into the 
surrounding medium.30  For this reason, nanoparticle formulations have been 
used to enhance the bioavailability of insoluble hydrophobic drugs.3  By 
suspending the drugs as nanoparticles, one can achieve a dose that is higher 
than that of a solution, which is thermodynamically limited by the aqueous 
solubility of the drug.6   
These properties of nanoparticles can be exploited in many ways to 
enhance a drug formulation.  For example, it is sometimes desirable to 
increase the octanol-water partition coefficient (log P) of drugs by modifying 
their structures with the addition of an aliphatic tail group.  Bhandari, et al. 
demonstrated this through ketorolac esterification with a fatty acid to enhance 
permeation though the skin, which is a hydrophobic barrier.31  Similar prodrug 
modifications have been used in other studies to the same effect.32-35  Several 
studies have demonstrated that fluorinated nicotinic acid esters have an 
increased solubility in perfluorooctyl bromide, which can be used as a delivery 
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vehicle for drugs to the lungs.36,37  Lehmler, et al. demonstrated that this 
prodrug strategy in conjunction with the perfluorocarbon delivery vehicle 
increased the partition of the lipophilic drug into lung epithelial cells.37  A 
nanoparticle formulation technique could be used to counteract the decrease 
in aqueous solubility that comes with the addition of hydrophobic groups to 
increase the local bioavailability of the drug. 
 In addition to the enhanced mass transfer properties offered by 
nanoparticles, several studies have demonstrated that nanoparticles bind to 
and can be internalized by a variety of cell types.38-42  Davda, et al. showed 
that vascular endothelial cells rapidly internalize nanoparticles into the 
cytoplasm.39  Another study demonstrated that pulmonary epithelial cells 
internalize particles 0.5 µm or smaller 10 times more than 1 µm particles and 
100 times more than 2 or 3 µm particles.40  These studies suggest that 
nanoparticle formulations may be an effective way to enhance drug 
internalization by cells. 
 
1.4. Nanoparticle Processing Methods for Pulmonary Drug Formulations 
Many chemical processing technologies have been used to produce drug 
nanoparticles suitable for pulmonary delivery.  Some processes that are 
currently under investigation involve wet milling,28,43 supercritical fluid 
extraction,44 spray drying,45,46 electrospray,21-23 high-pressure 
homogenization,47 and recrystallization via solvent displacement.48  Wet 
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milling is a process that utilizes either ceramic or metallic milling media to 
grind a suspension of insoluble drug and surfactant.  Merisko-Liversidge, et al. 
have shown that this technique can be used to produce Zn insulin 
nanoparticles using a roller mill that contains ceramic milling media and 
surfactants.43  The authors reported producing insulin nanoparticles less than 
200 nm in size.43  Wet milling has also been used to formulate budesonide for 
nebulized delivery to the lungs.28  Use of this technique for other poorly-water 
soluble drugs has been vindicated by SkyePharma, as evidenced by a recent 
patent.49  Spray drying is a process that forces fluid through a nozzle, 
producing a mist that is dried to produce a fine powder.  The technique 
employs a variety of different types of nozzles, some of which use ultrasound 
or air-jet shear to nebulize drug suspensions.  Supecritical fluid extraction is a 
technique that is currently being developed for use in nanoparticle drug 
formulations.  It uses supercritical fluid to extract a solvent from a drug 
emulsion or solution, leaving behind a suspension of drug particles.44  These 
processes are advantageous because they generally offer better scalability, 
and are therefore industrially relevant.  Unfortunately, some processes (such 
as spray drying) often utilize cosolvents to improve drying and/or large 
amounts of excipient to stabilize the drug and to maintain powder properties. 
In addition to chemical processing technologies, multiple recent studies 
have examined different polymeric nanoparticle fabrication methods as 
applied to pulmonary drug formulations.50-55  These techniques generally 
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involve polyelectrolyte complex formation, double emulsion/solvent 
evaporation techniques, or emulsion polymerization techniques.  
Polyelectrolyte complexes use oppositely charged polymers to entrap drugs 
into a polymeric matrix nanoparticle, which then releases the drug either 
through polymer degradation or drug diffusion.  Double emulsion/solvent 
evaporation techniques involve dissolving the drug and polymer in an organic 
solvent, which is then emulsified in an aqueous solution.  The organic solvent 
diffuses out of the polymer phase and into the aqueous phase, and is then 
evaporated, leaving behind drug-loaded polymeric nanoparticles.  Emulsion 
polymerization is similar to emulsion/solvent evaporation except that 
monomer is emulsified into droplets and then polymerization is initiated. 
 Liposomal formulations are typically produced by extruding or 
homogenizing a suspension of dissolved, hydrated lipids.56  This suspension 
can then be delivered via nebulization, freeze-dried, or incorporated into 
larger particles.  Liposomes produced in this manner have been dispersed 
into lactose and spray dried to produce nanoparticle-containing dry powders 
for pulmonary delivery.57  Aerosolized liposomes have been used for a variety 
of pulmonary drug delivery applications, including local delivery of 
chemotherapeutics to the lung,58 and systemic delivery of peptides.59 
 
1.4.1. Spray Drying to Produce Pure Drug Nanoparticles 
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Spray drying is a process that uses jets of drug nanoparticles suspended in 
an aqueous solution of lactose or other suitable bulking agent that are forced 
through high pressure nozzles to produce a fine mist.45  The aqueous or other 
liquid contents of the mist evaporate, leaving behind a fine powder.  A new 
modification of spray drying, called air nebulization spray drying, uses two 
wedge-shaped nozzles through which compressed air passes and two 
through which liquid solutions pass at high velocity.  The wedge-shaped 
nozzle acts as a fluid acceleration zone where the four streams collide at high 
velocity, producing a shock wave that generates fine droplets.  The droplets 
will then descend into a column while being dried into a solid powder by 
heated air before being collected. 
Mizoe, et al. have investigated this process as a means to produce 
nanoparticle-containing microparticles suitable for pulmonary drug delivery.60  
Briefly, pranlukast hemihydrate (PLH) was used as a water-insoluble model 
drug. The drug solution was prepared by dissolving PLH in a 1:1 solution of 
aqueous bicarbonate and ethanol.  Mannitol was dissolved in water for use as 
the microparticle carrier.  The solutions were then passed through the liquid 
passages of a spray dryer, as described above, and the resulting particles 
were collected and analyzed.  This method produced particles with a mean 
diameter of approximately 2 µm, which is within the respirable range.  The 
microparticles, being mostly mannitol, were dissolved in water, reportedly 
leaving behind a suspension of insoluble PLH nanoparticles within the size 
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range of 100 and 430 nm.60  Thus, the particles produced in this manner 
presumably would rapidly dissolve on the surface of the pulmonary epithelium, 
leaving behind drug nanoparticles that can slowly dissolve and release drug 
for systemic or local action. 
By using a similar method, Sham, et al. spray dried lactose with either 
gelatin or poly(butyl)cyanoacrylate nanoparticles to produce particles for 
pulmonary delivery.61,62  In one study, the authors produced gelatin 
nanoparticles by dissolving high molecular weight gelatin in water and stirring 
under constant heating at 40°C, and the pH was adjusted to 2.5.  Acetone 
was added drop-wise to the solution to precipitate the nanoparticles, which 
were then stabilized with 25% glutaraldehyde as a cross-linking agent.  The 
particles were then stirred for 12 hours to remove the residual solvent.  
Poly(butyl)cyanoacrylate nanoparticles were prepared by adding monomer 
drop-wise to a 0.01 N HCl solution.  The solution was then stirred for 4 hours 
and the pH was adjusted to 5.0 with 1 N NaOH.  Particle sizes were reported 
to be around 240 nm and 170 nm for the gelatin and poly(butyl)cyanoacrylate 
nanoparticles, respectively, by dynamic light scattering.62  Particles were then 
spray dried using a parallel flow nozzle, which sprays solution and drying air 
in the same direction to atomize the drug solution.  In this experiment, lactose 
was dissolved in water at about 7% weight per volume (5 g per 75 mL) and 
heated to increase the lactose solubility.  The solution was then mixed with 
one of the two nanoparticle suspensions (1:3 volume of nanoparticle 
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suspension to lactose solution) and spray dried.  The authors report 
producing powders with sizes of 2.50 µm, 2.59 µm, and 2.60 µm for pure 
lactose, lactose and gelatin nanoparticles, and lactose and 
poly(butyl)cyanoacrylate nanoparticles, respectively.62  The inclusion of the 
nanoparticles in the formulations did not significantly affect the particle sizes, 
as determined by a Student’s t-test.62  This study demonstrates that polymeric 
nanoparticles can be incorporated into larger particles with suitable sizes for 
pulmonary delivery.  The authors have also reported that these particles have 
applications as “cluster bombs” that can be used to deliver 
chemotherapeutics to lung cancer cells.  In another study, the authors 
demonstrated that polymeric and liposomal nanoparticles loaded with 
doxorubicin and spray dried with lactose in the manner described above were 
more effective at killing chemo-sensitive (H460 cell line) and chemo-resistant 
(A549 cell line) lung cancer cells than pure drug and unloaded nanoparticles. 
63 
 In another study, Yamamoto, et al. combined an emulsion/solvent 
evaporation technique with a modified form of spray drying to produce 
microparticles suitable for inhalation.64  Briefly, PLGA and the drug 6-
coumarin were dissolved in an ethanol and acetone mixture and injected into 
an aqueous polyvinylalcohol (PVA) solution while being stirred at 400 rpm, 
producing particles approximately 250 nm in diameter after evaporation of the 
organic phase.64  Lyophilized powder was then suspended in water containing 
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dissolved mannitol and spray dried in a fluidized bed granulation system.  In 
this process, solution is sprayed from the bottom of the reactor into the 
granulation chamber and the resulting mist was dried by heated air.  Dried 
particles were then entrapped onto a backdrop filter and redispersed into the 
granulation chamber with a pulsed air jet.  The authors hypothesize that the 
particles were granulated by the coalescence of wet and dry particle collisions 
within the granulation chamber.64  The authors report an aerodynamic 
diameter of the resulting particles between 1 and 10 µm, as measured by 
cascade impaction.64 
 Spray drying has also been used to create powders with effervescent 
properties for more active release in the lungs.  Ely, et al. prepared 
poly(butyl)cyanoacrylate nanoparticles as a model particle.65  The resulting 
nanoparticles were then suspended in a aqueous solution containing citric 
acid, sodium carbonate, polyethylene glycol 6000 and L-leucine.65  The 
suspension was then spray dried to produce particles with an aerodynamic 
diameter of 2.17 µm.  The authors reported that, when dissolved in water, the 
effervescent particles demonstrated more active release of nanoparticles as 
compared to lactose control particles, as determined by the large (~30 µm) 
nanoparticle-filled bubbles that were observed with the effervescent 
powders.65  This type of formulation could decrease the residence time of the 
microparticles in the lung tissue, potentially decreasing the chance of being 
phagocytized by alveolar macrophages, thus possibly enhancing the 
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bioavailability of the drug.  Further research should be done in this area to 
evaluate the potential benefits of this type of formulation. 
 Spray freeze-drying into liquid (SFL) is a variation of spray drying that 
atomizes drug and excipient streams into a cryogenic liquid to produce frozen 
particles.  The particles are then collected and lyophilized to obtain a dry 
powder. 45,46  Hu, et al. demonstrated that this process could be used to 
produce danazol nanoparticle-containing microparticles with fast dissolution 
rates.45  In another study, Purvis, et al. showed that this process can be used 
to engineer intraconazole-containing particles suitable for pulmonary delivery, 
using polyvinylpyrrolidone as the excipient.46  After spray freeze-drying, the 
particles were dispersed in saline solution, then nebulized and administered 
to mice as a prophylactic treatment against Aspergillus flavus infection.  Mice 
treated with nebulized SFL particles, as well as an evaporative precipitation of 
aqueous intraconazole as a control, had a greater chance of survival than 
mice that were not inoculated.46  The authors did not report a significant 
difference in prophylactic ability between the nebulized particles and the 
aqueous intraconazole control. 
 
1.4.2. Supercritical Fluid Extraction to Produce Pure Drug Nanoparticles 
Supercritical fluid extraction is a chemical process that uses a supercritical 
fluid (often scCO2) to extract solvent or other impurities from a suspension.  
Supercritical carbon dioxide usage has gained popularity recently because it 
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is an environmentally benign solvent that can be harmlessly vented into the 
atmosphere.66  Additionally, because carbon dioxide is a gas at ambient 
temperature and pressure, it can simply be flash vaporized at atmospheric 
pressure, leaving behind any extracted solvent and impurities.  This 
eliminates the extraction medium stripping step from the process, making it 
more economical and less energy intensive than traditional extraction and 
stripping processes.  Recently, Chattopadhyay, et al. used a continuous 
supercritical carbon dioxide extraction process to produce solid lipid 
nanoparticle suspensions for pulmonary delivery.44  In this process, 
supercritical carbon dioxide was used to extract organic solvent from an oil in 
water emulsion containing one of three lipids (tripalmitin, tristearin, or gelucire 
50/13), and one of two model drugs (indomethacin, or ketoprofen).44  One of 
the aforementioned lipids and drugs was dissolved in chloroform with a soy 
lecithin surfactant, then dispersed into an aqueous solution containing sodium 
glycocholate and homogenized under high pressure to produce the 
emulsion.44  This reportedly created an emulsion with a mean droplet size 
ranging between 30 and 100 nm, which was introduced into an extraction 
column countercurrently to a stream of supercritical carbon dioxide.  The 
scCO2 extracted the organic solvent from the dispersed droplets, leaving 
behind solid lipid, drug-containing particles in an aqueous suspension. 44  This 
processing method produced nanoparticles with a volume mean diameter 
between 10 and 30 nm, and a drug loading efficiency between 80 and 90% 
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for the gelucire particles and 10% for the tripalmitin particles.  Nebulized 
droplets were produced from the suspensions within an aerodynamic 
diameter range between 2 and 4 µm, which is within the respirable range.44  
Thus, supercritical fluid extraction might be an effective means to produce 
drug-loaded nanoparticles within a suitable size range for pulmonary delivery 
as a nebulized aerosol. 
 
1.4.3. Methods to Produce Polymeric Nanoparticle Formulations 
Several studies have examined different polymeric nanoparticle formulation 
techniques and their suitability for pulmonary drug delivery applications.  
These techniques generally involve polyelectrolyte complex formation,67 
double emulsion/solvent evaporation techniques,53,55,67 or emulsion 
polymerization methods.54  In polyelectrolyte complex formation, a polycation 
and a polyanion are dissolved (usually in water), then mixed under moderate 
shear to generate nanoparticles.  Alternatively, a single polyionic material can 
be complexed with an oppositely charged drug and then gelled with an 
oppositely charged, multivalent salt.52  Other studies have condensed DNA (a 
polyanion) with a polycation to produce nanoparticles for pulmonary gene 
delivery.67  Double emulsion methods typically dissolve a polymer such as 
PLGA in an organic solvent, which is then emulsified under shear in aqueous 
solvent containing surfactants.  The organic solvent is then typically 
evaporated, leaving a colloidal suspension of solid nanoparticles. 50,51,53,55  
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Emulsion polymerization methods involve adding a liquid monomer to an 
aqueous solution containing surfactants and applying shear, which is followed 
by polymerization of the dispersed phase.  For example, this technique 
sometimes employs (poly)cyanoacrylates, which polymerize in water, thus 
eliminating the need for an initiator.54 
Grenha, et al.,52 produced nanoparticles using an ionotropic gelation 
method.  Chitosan and tripolyphosphate (TPP) were dissolved in aqueous 
solutions and mixed under mild stirring to spontaneously precipitate 
nanoparticles.  Insulin was dissolved in 0.01 M NaOH solution and added to 
the TPP solution before being added to the chitosan solution.  Particles with 
sizes ranging from 300 to 500 nm and with zeta potentials between +32 to 
+45 mV were produced in this manner.  The authors found that increasing the 
chitosan to TPP mass ratio decreased the process yield (mass of particles 
produced over total mass), but increased the size and zeta potential of the 
particles.52  The particles decreased in size when incubated in a lysozyme 
solution (due to hydrolysis of the β-(1-4) glycosidic linkages in chitosan), 
suggesting that they will degrade in the pulmonary epithelium and release 
their drug contents.  These particles were then incorporated into 
microparticles by incubating them in lactose and mannitol excipient solutions 
and spray drying.  This process produced microparticles with aerodynamic 
diameters between 2 and 3 µm, which are suitable for pulmonary delivery.52  
The microparticles rapidly dissolved in aqueous solution, leaving behind a 
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suspension of nanoparticles.  The authors conclude that these particles can 
be used to effectively deliver therapeutic macromolecules to the lungs and 
promote pulmonary absorption.52 
 In a recent study,68 the authors demonstrate that the same 
chitosan/TPP nanoparticles can be incorporated into phospholipid 
microparticles using a lipid film evaporation method.  Briefly, the 
phospholipids dipalmitoylphosphatidylcholine (DPPC) or a mixture of DPPC 
and dimyristoylphosphatidyl glycerol (DMPG) (10:1 molar ratio) was dissolved 
in chloroform and evaporated.  The resulting lipid film was then hydrated with 
a suspension of nanoparticles.68  The resulting microparticles were reported 
to have an aerodynamic diameter between 2.1 and 2.7 µm, making them 
suitable for delivery to the peripheral lung.68 
 Another method of nanoparticle synthesis described by Dailey, et al. 
capitalizes on both ionotropic complexation and solvent displacement 
techniques.51  The authors developed a novel branched polyester, 
diethylaminopropyl amine-poly(vinyl alcohol)-grafted-poly(lactide-co-
glycolyde) (DEAPA-PVAL-g-PLGA), which contains a degradable PLGA 
backbone and a cationic tertiary amine group.  The authors hypothesize that 
the additional hydrophilic derivatization can increase the degradation rate of 
the polymer by increasing the degree of water saturation.51  To formulate the 
nanoparticles, the DEAP-PVAL-g-PLGA polymer was dissolved in acetone 
and injected into water containing a buffer and carboxymethyl cellulose 
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(CMC); a polyanion.  The resulting suspension was then stirred under 
reduced pressure to remove the organic solvent.  The authors found that the 
ratio of polymers had a great impact on both the particle size and the zeta 
potential.  As the concentration of CMC increased, the zeta potential 
decreased, and as the zeta potential approached neutrality, the particle size 
increased.  Additionally, as the concentration of the CMC increased further, 
the zeta potential continued to decrease, and the particle size began to 
decrease.  The authors suggest that this is most likely due to increased 
particle agglomeration as the surface charge approaches neutrality, thereby 
diminishing Coulombic forces between particles.51  The authors found that the 
increased hydrophilicity of the nanoparticles increased the rate of degradation 
as compared to pure PLGA particles.  They also observed that the more 
neutral the zeta potential of the particles, the less rapidly they degraded over 
time, presumably due to an increase in lipophilicity.51  This study also 
reported an increased stability in negatively charged particles after 
nebulization.51  In a later study, the authors showed preliminary evidence that 
particles produced in the same manner possess a decreased inflammatory 
potential in the lung compared to non-degradable, lipophilic polystyrene 
particles of similar size.50  Thus, particles produced in this manner may have 
potential as a pulmonary drug delivery vehicle that degrades relatively rapidly 
and does not cause inflammation. 
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 Another study utilized both polyionic complexation and solvent 
displacement to develop a PLGA polyethylenimine (PEI) nanoparticle 
complexed with DNA for gene delivery to the pulmonary epithelium.67  Bivas-
Benita, et al. dissolved PLGA and PEI in dichloromethane, and added Tween-
80 and acetone.  This solution was injected into an aqueous phase containing 
Poloxomer-188 as a surfactant, and stirred slowly to evaporate the organic 
phase.67  The resulting particles were filtered, and then complexed with DNA.  
To achieve this, a nanoparticle suspension was added to a DNA solution and 
vortexed.  Particles were created at varying PLGA-PEI ratios and PEI-DNA 
ratios.67  This method consistently produced particles with sizes between 207 
and 231 nm, regardless of the PLGA-PEI and PEI-DNA ratios used.  The 
authors also observed that the zeta potential was not affected by the PLGA-
PLA ratio, but was dependent on the PEI-DNA ratio.67 
 Shi, et al. have shown that oppositely charged nanoparticles can be 
assembled to form larger, low density microstructures suitable for pulmonary 
delivery.53  In this study, PLGA nanoparticles were produced using a solvent 
evaporation procedure.  Briefly, PLGA was dissolved in acetone and 
methanol, then injected at a controlled rate into an aqueous solution 
containing either dissolved poly(ethylene-maleic anhydride) (PEMA) or 
poly(N-vinyl formamide) (PVAm) under homogenization.  The residual 
acetone was then evaporated, and the remaining particles were collected.  
Particles produced in the PEMA solution were around 300 nm in diameter 
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with a zeta potential of around -50 mV, and particles produced in PVAm 
solution were slightly larger at around 500 nm and with a zeta potential of 
around +30 mV.  The difference in zeta potential was due to the charges of 
the coating polymers, PEMA being a polyanion and PVAm a polycation.53  A 
suspension of the PVAm-coated particles were then injected into a 
suspension of PEMA-coated particles under homogenization to destabilize 
the colloid and cause particle flocculation; induced by the ionic interactions 
between particles in suspension.  The authors found that lyophilized samples 
of the nanoparticle flocculates has aerodynamic diameters between 2 and 4 
µm, making them ideally sized for pulmonary delivery.53  Additionally, SEM 
images showed that the nanoparticle flocculates had irregular geometries and 
were largely porous structures, which would increase their flowability in a dry 
powder inhaler.53 
 PLGA is often favored as a polymeric excipient for drug delivery 
because of its biodegradability and biocompatibility.  In a study by Pandey, et 
al., PLGA nanoparticles were prepared using a multiple emulsion/solvent 
evaporation technique similar to those previously described.55  The authors 
produced nanoparticles containing rifampicin, isoniazid, or pyrazinamide, 
which are used to treat tuberculosis.  Briefly, aqueous drug solution was 
emulsified in a dichloromethane solution containing PLGA polymer via probe 
sonication.  The emulsion was then added to an aqueous solution containing 
polyvinyl alcohol and sonicated.  The resulting solution was then stirred 
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overnight to remove the organic phase, and particles were collected via 
centrifugation.55  This technique produced particles with sizes ranging 
between 180 and 300 nm and a drug encapsulation efficiency between 50 
and 70%, depending on the drug used.  The particle suspensions were then 
nebulized, reportedly producing droplets between 1.1 and 2.1 µm, which is 
within the respirable range.55 
 Another method of nanoparticle synthesis is emulsion polymerization, 
where a monomer emulsion is prepared and polymerized as nanoparticles.  
Studies suggest that cyanoacrylates are popular monomers for this method, 
most likely because of their water-initiated polymerization process.  In a study 
by Zhang, et al., insulin-loaded poly(butyl)cyanoacrylate nanoparticles were 
produced by injecting α-butyl-cyanoacrylate drop wise into an aqueous 
solution containing Dextran 70.54  After 1 hour of agitation, insulin solution 
was added and agitation was continued for another 2 hours.  This processing 
method reportedly produced particles with sizes ranging between 160 and 
400 nm and an insulin association ratio of 79.1%.54  Interestingly, the in vitro 
release profiles of the insulin nanoparticles were biphasic, consisting of a 
burst phase followed by a zero-order release phase.  The authors 
hypothesize that this is most likely due to the rapid dissolution of insulin 
adsorbed to the surface of the particles, followed by sustained release of 
insulin contained within the particles.54  The authors also observed a 
prolonged hypoglycemic effect in rats when the particles were administered 
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intratracheally as compared to an insulin solution delivered via subcutaneous 
bolus.54  This study suggests that insulin, and possibly other small peptide 
drugs, can be adsorbed onto nanoparticles and delivered to the lungs to 
produce a range of release profiles. 
 
1.4.4. Methods to Produce Liposomal Nanoparticle Formulations 
Liposomal nanoparticles have been investigated as potential drug carriers to 
the lung.  Many lipids commonly used in liposome preparation are already 
abundantly present in the lungs, thus they should be well tolerated by the 
lungs.56 Additionally, the great diversity of amphiphilic molecules available for 
constructing liposomes provides enormous versatility in particle size and 
physical parameters, making them highly attractive for creating a variety of 
drug delivery vehicles.69  A possible concern is that lipids themselves modify 
the surface tension of the lungs and have themselves been used as 
therapeutics.70,71 
 In general, liposomes are interesting potential drug delivery vehicles 
because of their stability in suspension.  For instance, upon dilution or 
changes in ionic strength that may be encountered during administration, 
liposomes will theoretically remain intact.  This is because liposomal 
formulations are not thermodynamically equilibrated systems, but are 
kinetically trapped systems that are unable to respond to thermodynamic 
perturbations.69  This property might make them suitable for formulations that 
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require long-term storage as liquid suspensions, such as those used in 
nebulization. 
Liposomes have also been investigated as potential targeting agents 
for alveolar macrophages,72,73 partially because macrophages are associated 
with lung surfactant metabolism.72  Studies have also shown that 
mannosylation of liposomal nanoparticles72,73 and particle size72 influence the 
uptake of liposomes by macrophages.  The studies demonstrate that 
liposomal uptake increases as particle size increases over a range of 100 to 
2000 nm,72 and as the degree of mannosylation increases on the surface of 
the particles.72,73  The authors suggest that this is likely due to the fact that 
mannose receptors are exclusively expressed on the surface of alveolar 
macrophages.73 
In addition to their ability to target alveolar macrophages, liposomes 
have been investigated because of their surface chemistries, which can be 
modified with chemical linkers to produce liposome agglomerates.56  Bhavane, 
et al. developed a novel type of drug delivery vehicle composed of liposomal 
nanoparticles covalently linked by enzymatically-labile spacers.  In this study, 
liposomes were prepared by extruding a suspension of dissolved, hydrated 
lipids.56  The lipid mixture included dipalmitoylphosphatidylcholine (DPPC), 
cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine-
poly(ethylene glycol)-amine (DSPE-PEG-NH2), which contains a amine group 
suitable for conjugation.56  This process reportedly produced liposomes 
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between 80 and 195 nm in size.56  Liposomes were loaded with ciprofloxacin 
with 90% efficiency.56  Agglomeration was induced using dimethyl 3,3’-
dithiobispropionimidate 2HCl (DTBP), which is a homobifunctional imidoester 
capable of reacting with primary amines and also contains thiol-cleavable 
disulfide bonds, making it enzymatically labile.56  The authors found that at 
low pH, smaller agglomerates were produced due to the restricted activity of 
the linker.  The agglomerated liposomes demonstrated slower release 
kinetics than the unagglomerated liposomes, and a burst effect was observed 
at time points when dithiothreitol (a disulfide bond reducing agent) was added 
to the dissolution medium.  Upon nebulization, the agglomerated particles 
were reported to retain the encapsulated drug and nebulized droplets had 
aerodynamic diameters between 1 and 5 µm, putting them within the 
respirable range.56  This study reports that controlled agglomeration of 
liposomal nanoparticles can be achieved, and that these particles can be 
nebulized into the respirable range. 
Liposomal formulations have also been investigated in potential dry 
powder formulations.  Chougle, et al. loaded nano-sized liposomes with 
tacrolimus, an immunosuppressant often used to prevent rejection of 
allotropic lung transplants.  The authors used a thin film evaporation 
technique, which included dissolving the drug and lipids (hydrogenated 
phosphatidylcholine and cholesterol) in methanol and chloroform, followed by 
solvent evaporation.57  The liposomes were then hydrated using PBS, and the 
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resulting suspension was passed through a high-pressure homogenizer to 
produce particles approximately 140 nm in diameter.  The nanoparticles were 
then suspended in an aqueous solution containing either lactose, sucrose, or 
trehalose and L-leucine and spray dried to produce microparticles with an 
aerodynamic diameter of approximately 2.2 µm that demonstrated good 
aerosolization properties when administered from a DPI.57  This study 
reportedly demonstrates that liposomal nanoparticles have potential use in 
dry powder pulmonary formulations. 
 
1.5. Toxicity Considerations of Nanoparticle Formulations 
A major concern with nanoparticle therapeutics is the unforeseen negative 
health impact that nanoparticles may have.  Studies in rodents have shown 
that intratracheally-administered carbon nanoparticles accelerate vascular 
thrombosis.74  Additionally, it has also been demonstrated that inhaled iridium 
particles may migrate from the lung to the systemic circulation, which may 
have detrimental vascular effects,75,76 and inhaled carbon nanoparticles have 
been shown to migrate to the brain, although their CNS toxicity remains to be 
determined.77  Conversely, a recent study has shown that metallic 
nanoparticles are no less cytotoxic than metallic microparticles, suggesting 
that the small size of nanoparticles may not be the most important factor 
affecting their toxicity.78  This notwithstanding, the toxicity of nanoparticles is a 
legitimate concern and should be thoroughly investigated. 
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 In addition to the possible inherent toxic effects of nanoparticles, some 
materials used to formulate nanoparticles may have toxic effects and 
therefore may not be viable for developing therapeutic products.  For example, 
the toxicity of polycyanoacrylates has been demonstrated by Brzoska, et al.  
The authors prepared poly(butyl)cyanoacrylate and poly(hexyl)cyanoacrylate 
nanoparticles in a method similar to that described by Zhang, et al.,54 using 
either Dextran 70 stabilizer or poloxamer 188.79  They determined that both 
types of nanoparticles caused an increase in lactate dehydrogenase (LDH) 
activity in human pulmonary epithelial cells.  The degree of toxicity was 
greater for the poly(butyl)cyanoacrylate and independent of the stabilizer 
used, which stands to reason because shorter chain polycyanoacrylates have 
been associated with higher cytotoxicity.79  The degree of toxicity also 
increased with increasing nanoparticle concentration,79 most likely due to the 
subsequent increase in polycyanoacrylate concentration.  Polyethyleneimine 
(PEI) has also demonstrated cytotoxicity in lung cells.80    Bivas-Benita, et al. 
showed that when PEI-DNA complexes were used to deliver DNA to lung 
epithelial cells, cell viability decreased as the PEI-DNA ratio increased.67  
Despite this, Dailey, et al. have shown that PLGA nanoparticles induce less 
inflammation than polystyrene particles of similar size when delivered to the 
lungs.50  Based on this observation, nanoparticle toxicity in the lungs may be 
more dependent on material choice than particle size.  Therefore, there may 
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be alternative polymers that can be investigated for use in pulmonary 
nanoparticle drug formulations that could mitigate toxicity. 
 
1.6. Future Directions 
Nanoparticle drug formulations offer many advantages over traditional aerosol 
powders and liquid pulmonary dose formulations.  For example, the 
bioavailability of poorly water-soluble drugs can be greatly enhanced by the 
large surface area of drug nanoparticle formulations.  Additionally, 
nanoparticles can be formulated in such a way to offer enhanced control over 
the morphology of dry powder drug formulations and the ability to produce 
structures with both a low-density microstructure for delivery to the deep lung 
and nanostructure for enhanced dissolution and bioavailability. 
 The literature suggests many different formulation approaches for 
drugs that use a variety of excipients to fabricate nanoparticles or 
nanoparticle complexes suitable for pulmonary delivery.  Many chemical 
processing techniques such as supercritical fluid extraction and spray drying 
have been successfully used for therapeutic nanoparticle processing.  
Additionally, polyelectrolyte complexation, double emulsion and solvent 
evaporation, emulsion polymerization, and liposomal loading offer a range of 
formulation options.  This diverse array of techniques has demonstrated the 
ability to effectively produce nanoparticles with a high degree of control over 
particle properties; however residual solvents, cytotoxic excipients, low drug 
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loading efficiencies and scale-up issues might limit their commercial 
applications.  With the perfection of pulmonary nanoparticle drug formulations, 
the lungs may become a preferred route of drug delivery for many local and 
systemic therapeutic interventions. 
 
2. Design of a Nanoparticle-Based Pulmonary Insulin Formulation 
Diabetes mellitus is a set of diseases characterized by defects in insulin 
utilization, either from autoimmune destruction of insulin-producing cells 
(Type I) or insulin resistance (Type II).  As of 2005, 20.8 million people in the 
United States (7.0% of the population) suffered from diabetes, and it was the 
sixth leading cause of death due to the many complications associated with 
this disease, such as pulmonary hypertension and ischemia.81  Current 
treatment methods involve regular injections of insulin, which can be both 
painful and inconvenient, thus often leading to low patient compliance.82 
 In order to overcome this problem, other routes of insulin 
administration have been investigated.  Inhaled aerosols have been shown to 
be an effective means to treat local diseases of the lung.83  Additionally, the 
large surface area of the lungs (~140 m2) and their ready access to systemic 
circulation makes them a possible candidate for noninvasive, systemic drug 
delivery.  This is particularly good for macromolecular drugs such as peptides, 
proteins, and DNA.83-85 
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 Sufficient deposition of aerosol particles in the peripheral lung requires 
precise control over particle size and density, which greatly affect the region 
of deposition in the lungs.7,84-88  Particles possessing an aerodynamic 
diameter in the range of 1-5 µm are required for suitable terminal bronchiole 
and alveolar deposition,7,86,88,89 as a means to access systemic 
bioavailability.87  Low-density particles are currently being developed as a 
means to deliver drugs to the distal regions of the lungs.85,87,90,91  These 
particles possess large geometric diameters, but smaller aerodynamic 
diameters due to their low density, as described by the following 
equation,7,53,86 
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Where ρref is a reference density (for example 1 g/cm3) and γ is the shape 
factor (equal to 1 for a sphere). 
 Studies have shown that insulin delivered via the pulmonary route is 
well tolerated and effective in treating patients with Type I diabetes.89,91-97  
Currently, there are several inhaled insulin delivery systems in development.  
Of these, those employing the Technosphere (Mannkind Corporation) and 
Spiros technologies  (Dura Pharmaceuticals) are dry powder formulations.92  
The Exubera formulation (Nektar Therapeutics and Pfizer) and the 
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formulation using AIR technology (Alkermes and Eli Lilly) are other examples 
of dry powder formulations that were either FDA approved and discontinued 
(Exubera), or terminated during Phase III clinical trials (AIR).   One potential 
drawback to these formulations is that they contain excipients, which aid in 
manufacturing and aerosol performance, but may have unforeseen negative 
impacts on the long-term respiratory health of the patient.82,95  Of particular 
concern are penetration enhancers, such as polyoxyethylene 9 lauryl ether 
and sodium glycocholate, which have been shown to induce acute 
inflammation in the lung.98  It may therefore be desirable to create an 
inhalable form of insulin that does not contain excipients so as to avoid any 
potential complications that might arise.  Additionally, most of the current 
technologies use a spray drying technique to produce particles, which can 
subject the insulin to air/water interfaces, high temperatures, and other 
conditions that can cause the protein to denature. 
 Here, a dry powder Zn-insulin formulation possessing appropriate 
microstructure to reach the deep lung that is processed without excipients has 
been developed.  Factors such as pH and insulin concentration were shown 
to have an affect on seed nanoparticle size.  Circular dichroism (CD) and 
solid-state nuclear magnetic resonance (ssNMR) were used to show that 
irreversible secondary structure and crystallinity changes of the insulin did not 
occur as a result of processing.  It has been demonstrated that excipient-free, 
insulin microparticles that are suitably sized for pulmonary delivery and have 
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a high dissolution velocity can be produced with minimal processing steps.  
This development may help future researchers develop novel pulmonary 
delivery systems for the treatment of diabetes. 
 
2.1. Materials and Methods 
2.1.1. Materials 
Lyophilized insulin powder from bovine pancreas (0.5% zinc content) and 
phosphate buffered saline premix (PBS) were purchased from Sigma (St. 
Louis, MO).  All other reagents were purchased from Fisher Scientific 
(Pittsburgh, PA) and used without further purification. 
 
2.1.2. Fabrication of Insulin Nanoparticles 
Approximately 100 mg of insulin stock powder were dissolved in 15 mL of 
0.01 N HCl solution.  The solution was then titrated drop-wise to a pH just 
below the isoelectric point (pI) of the native protein (5.3) with 0.01 N NaOH 
solution, at which point the solution became colloidal without fully precipitating.  
The mean geometric diameters and polydispersities of the nanoparticle 
suspension were measured using dynamic light scattering (Brookhaven 
Instruments Zeta Potential Analyzer, Holtsville, NY).  Nanoparticles were 
diluted in deionized H2O (~100X) and three, 1 minute measurements were 
obtained at 25°C for each sample.  Mean size and polydispersity were 
determined by the method of cumulants.99  The same instrument was used to 
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determine the zeta potential (ζ) of the nanoparticles in 1 mM potassium 
chloride solution.  Three runs of 15 cycles were acquired, and the mean zeta 
potential was recorded.  Some samples were frozen at -80°C and lyophilized 
using a Labconco bench top lyophilizer (Kansas City, MO) for further analysis. 
A range of pH values near the pI of the native protein were determined 
in which the nanoparticle colloid was preserved.  Particle sizes and zeta 
potentials were measured for each sample.  Nanoparticle samples within this 
pH range (from 4.92 to 5.09) were centrifuged at 13,000 rpm for 10 minutes 
and the supernatant concentration of insulin was analyzed using UV 
absorbance spectroscopy (Agilent 8453).  All pH values were measured in 
triplicate.  The measured concentration was used to calculate the mass of 
insulin in the pellet from the original insulin mass and total volume. 
 
2.1.3. Agglomeration of Insulin Microparticles 
Aliquots of insulin nanoparticle suspensions (5 mL) were added to 15 mL of 
ethanol and stirred for ~36 hours at 300 rpm under a fume hood.  
Nanoparticles with diameters of approximately 200 nm were selected for this 
step.  The geometric diameters of the insulin microparticles were measured 
using a Coultier Multisizer 3 (Beckman Coultier, Fullerton, CA).  Samples 
were then frozen at -80 °C and lyophilized for further analysis. 
 
2.1.4. Characterization of Aerosol Properties 
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The aerodynamic diameters of the lyophilized powders were determined 
using an Aerosizer LD (Amherst Process Instruments Inc.).  Data were 
collected over ~70 seconds under high shear force (~6 psi) using a 700 µm 
aperature. 
 
2.1.5. Characterization of Particle Morphology 
The size and morphology of lyophilized samples were evaluated using a LEO 
1550 field emission scanning electron microscope (SEM).  All samples were 
sputter-coated with gold for 30 seconds prior to imaging. 
 
2.1.6. Conformational Stability of Processed Insulin 
Post-processing secondary structural changes in samples were analyzed by 
dissolving particles in 0.01 N HCl solution and analyzing using circular 
dichroism spectroscopy (CD; Jasco J-810, Easton, MD) to determine 
conformational differences between processed and unprocessed insulin, as 
well as thermal stability differences between groups.  CD spectra were 
acquired in three accumulations from 260-195 nm with a scanning speed of 
50 nm/min and 1.0 nm resolution.  Thermal stability was determined at a 
wavelength of 210 nm from 10-80 °C with a scanning speed of 15 °C/hr.  
Thermal stability spectra were acquired in triplicate.  Insulin concentration in 
prepared solutions was determined by UV absorbance spectroscopy. 
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2.1.7. Crystallinity of Processed Insulin 
2.1.7.1. NMR 
Spectra were collected using a Tecmag Apollo spectrometer operating at 300 
MHz using ramped amplitude cross-polarization (RAMP),100 magic-angle 
spinning (MAS),101 and SPINAL-64 decoupling.102  Samples were packed in 4 
mm o.d. zirconia rotors using Teflon® encaps, and spun at 8 kHz in a 
ChemagneticsTM Triple-Resonance HXY CP/MAS NMR probe configured to 
run in double-resonance mode using the H and X channels, and fitted with a 4 
mm spin module from Revolution NMR.  All spectra are the sum of 120,000 
transients collected using a 1.5 s pulse delay, a contact time of 2 ms, and a 
1H 90° pulse width of 2.3 µs.  The free induction decays consisted of 256 
points with a dwell time of 33.3 µs.  The spectra were externally referenced to 
tetramethylsilane using the methyl peak of 3-methylglutaric acid at 18.84 
ppm.103 
 
2.1.7.2 HPLC 
The crystalline insulin content of the materials was determined using the 
method in the insulin zinc suspension monograph of the 2005 U.S. 
Pharmacopoeia National Formulary, with minor modifications.  Buffered 
acetone TS was produced by dissolving 8.15 g of sodium acetate and 42 g of 
sodium chloride in 100 mL of water, to which 68 mL of 0.1 N hydrochloric acid 
and 150 mL of acetone were added, the mixture was then diluted with water 
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to make 500 mL.  Approximately 0.5 mg of insulin was placed in a 1.5 mL 
microcentrifuge tube and 33.3 µL of a 1:2 mixture of water and buffered 
acetone TS was added to the tube to extract any amorphous insulin.  The 
sample was immediately centrifuged at 13,000 rpm for one minute, the 
supernatant was decanted, and the extraction was repeated.  Additionally, 
~0.5 mg of insulin was placed in another microcentrifuge tube to be used as a 
control.  Both insulin samples were each dissolved in 33.3 µL of 0.01 N 
hydrochloric acid and analyzed by HPLC, with each sample being prepared in 
triplicate.   
 The HPLC was a Shimadzu system that consisted of an SCL-10A 
system controller, LC-10AT liquid chromatography pump, SIL-10A auto 
injector with a sample cooler, and SPD-10A UV-VIS detector with instrument 
control and data analysis performed through CLASS-VP software.  Aqueous 
mobile phase was prepared by dissolving 28.4 g of anhydrous sodium sulfate 
in 1000 mL of water, to which 2.7 mL of phosphoric acid was added and the 
pH was adjusted to 2.3 with ethanolamine.  The aqueous mobile phase was 
then mixed 74:26 with acetonitrile.  The separation was performed on a 4.6 x 
250 mm Symmetry® C18 column from Waters that was maintained at 40°C.  
Samples were maintained at 5°C and 20 µL were injected for analysis, with a 
mobile phase flow rate of 1 mL/min and the detector set to 215 nm.  Peak 
areas were normalized to the mass of insulin used to prepare the sample and 
the percent crystalline insulin was calculated with the following equation: 
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 %Crystalline =
SamplePeak
ControlPeak
!100  [2] 
 
2.1.8. Dissolution of Insulin Particles 
Approximately 6 mg of each insulin particle sample was suspended in PBS 
(pH 7.4).  The solution was placed in a 100,000 Dalton biotech grade 
cellulose ester dialysis tube (Spectrum Labs, Rancho Dominiguez, CA) and 
placed in PBS solution to a final volume of 45 mL.  All samples were 
incubated at 37°C and shaken at 50 rpm on a shaker table.  1 mL aliquots 
were taken at various time points up to 8 hours from the bulk solution and 
replaced with 1 mL of fresh PBS.  The insulin concentration was measured 
using a Coomassie Plus colorimetric protein quantification assay (Thermo 
Fisher Scientific, Waltham, MA).  A calibration curve was used to correlate the 
insulin concentration with the measured absorbance, with insulin 
concentrations ranging between 1 and 25 µg/mL being used as the standard.  
Dissolved mass was calculated from the measured concentration, and was 
then normalized to the total loaded mass to determine the percent dissolved.  
All experiments were performed in triplicate.  Analysis of variance (ANOVA) 
was used to determine statistically significant differences between groups (p < 
0.05).  Comparisons among groups were done using a Fisher’s F-test. 
 
2.1.9. Estimation of Bulk Powder Density 
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The bulk density of the dry powder was estimated using a micro-tap test 
approach, as defined in the U.S. Pharmacopoeia National Formulary, with 
slight modifications.  Briefly, dry powder samples (unprocessed insulin, 
nanoparticles, and microparticles) were added to pre-weighed microcentrifuge 
tubes, and the tubes were weighed again to determine the mass of powder.  
The tubes were then tapped thirty times on the lab bench to compress the 
powder.  The volume of the powder was approximated by comparing the 
height of the compressed powder to that of a volume of water in an identical 
pre-weighed microcentrifuge tube.  The tube containing the water was then 
weighed to determine the volume of water (assuming a density of 1 g/mL).  
The powder density was calculated by dividing the mass of powder by the 
volume of water.  All samples were analyzed in triplicate.  Analysis of 
variance (ANOVA) was used to determine statistically significant differences 
between groups (p < 0.05).  Comparisons among groups were done using a 
Fisher’s F-test. 
 
2.2. Results 
2.2.1. Characterization of Insulin Nanoparticles 
Zn insulin nanoparticles were created by titrating dissolved insulin to the pI of 
the native protein, which resulted in a colloidal suspension of nanoparticles.  
Particle sizes and zeta potentials were analyzed over a pH range of 4.92 to 
5.09, and ranged from 292 nm to 593 nm (Table I).  Zeta potentials ranged 
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from 10.8 mV to 18.9 mV.  Neither particle sizes nor zeta potentials correlated 
strongly with the pH of the solution. 
 
 The mass fraction of insulin remaining in solution after nanoparticle 
precipitation was determined using UV absorbance spectroscopy.  These 
values were used to determine the mass fraction of total insulin contained in 
the nanoparticles.  The results suggest a positive correlation between the 
particle size and the total mass of the insulin nanoparticles in suspension 
(Figure 1). 
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Figure 1.  Mass fraction of insulin in pellet vs. pH.  Each value represents mean ± S.D. of 
three experiments. 
 
2.2.2. Characterization of Insulin Microparticles 
Insulin microparticles were produced from insulin nanoparticle suspensions 
through solvent displacement.  This was achieved by adding aliquots of 
insulin nanoparticle suspension to ethanol and stirring overnight.  The 
geometric diameter of the insulin microparticles was determined to be 3.4 ± 
1.4 µm.  No correlation was determined to exist between insulin nanoparticle 
size and microparticle size.  SEM imaging revealed differences in the 
morphology of the unprocessed insulin and the insulin microparticles (Figure 
2).  The unprocessed insulin agglomerates appear to have a more regular 
structure, while the microparticles have more of a leaf-like morphology.  This 
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leaf-like shape could aid in the aerosolizability of the insulin microparticles, 
and would suggest a shape factor (as defined in Equation 1) of less than 1. 
 
Figure 2.  SEM micrographs of insulin particles; (A) and (B) are unprocessed insulin particles 
(scale bars 30 µm and 10 µm, respectively); (C) and (D) are insulin microparticles after 
processing (scale bars 10 µm and 2 µm, respectively). 
 
2.2.3. Aerosol Properties of Insulin Particles 
The aerodynamic diameters of the unprocessed insulin powder, lyophilized 
insulin nanoparticles, and lyophilized insulin microparticles were measured 
with an Aerosizer LD and are shown in Table II.  The geometric diameters of 
the unprocessed insulin and the nanoparticles (marked with an *) were 
measured after resuspending lyophilized powder in aqueous solution, and the 
microparticles were measured in solution before lyophilization.  The large 
aerodynamic diameter of the insulin nanoparticles is most likely due to 
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uncontrolled agglomeration, which probably occurred during lyophilization.  
The smaller aerodynamic diameter of the insulin microparticles compared to 
the geometric diameter of the microparticles was expected because of the 
lower density of the insulin microparticles (Figure 3). 
 
 
Figure 3.  Tap density of insulin powders.  Each bar shows mean ± S.D. of three 
experiments. 
 
The size distributions of the geometric diameters are shown in Figure 4, 
which correspond to the mean values of the geometric diameter listed in 
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Table II.  The highly irregular dispersion of the nanoparticle sizes is likely due 
to agglomeration that can occur during lyophilization.  
 
Figure 4.  Size distributions of the geometric diameters of insulin powders.  Samples marked 
with an * were lyophilized and resuspended in aqueous solution before measuring. 
 
2.2.4. Conformational Stability of Processed Insulin 
Circular dichroism (CD) was employed to analyze the secondary structure 
and thermal stability of processed insulin powders.  Isothermal scans of 
dissolved, unprocessed insulin powder, dissolved nanoparticles, and 
dissolved microparticles reveal near-identical spectra with minima at 210 nm, 
suggesting that any changes in secondary structure that might occur during 
processing were reversible upon dissolution (Figure 5).  This overlap was also 
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reflected in the thermal stability CD scans, which show a slight change in 
molar ellipticity from 10-80°C starting at about 50°C for all samples. 
 
Figure 5.  Circular dichroism of dissolved insulin powders.  The top panel shows isothermal 
spectra, and the bottom panel shows variable temperature scan at a wavelength of 210 nm.  
Each value of the variable temperature scan represents mean ± S.D. of three experiments. 
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2.2.5. Crystallinity of Processed Insulin 
The crystallinity of the insulin particles was examined using 13C CP/MAS 
NMR (Figure 6).  The spectra display differences in the aliphatic region (~0 to 
75 ppm), although these differences are difficult to correlate with the physical 
state of insulin.  More obvious differences between the samples arise in the 
carbonyl (~175 ppm) and aromatic (~137 ppm) regions.  The peak at ~137 
ppm in the unprocessed insulin seems to be more narrow and better resolved 
than peaks at ~129 ppm.  These same lines in the other samples are broader, 
to the point where peaks at ~129 ppm cannot be resolved.  The peak at ~175 
ppm in the unprocessed insulin is more narrow, with two very clear shoulders 
at ~180 ppm and ~173 ppm.  Other samples only show one broad peak at 
~175 ppm.  The more defined peaks of the unprocessed insulin samples may 
suggest that the unprocessed insulin is more crystalline than the 
nanoparticles and the microparticles, however a robust interpretation of these 
data is difficult to ascertain. 
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Figure 6.  13C CP/MAS NMR spectra for insulin powders; (A) Unprocessed; (B) Lyophilized 
insulin microparticles; (C) Lyophilized insulin nanoparticles; (D) Centrifuged and dried insulin 
nanoparticles. 
 
 Crystallinity of the insulin particles was also examined using the 
buffered acetone method described in the U.S. Pharmacopoeia National 
Formulary.  The results suggest that the unprocessed insulin particles are 
between 80% and 88% crystalline, which is much greater than both the 
nanoparticles and microparticles, which were estimated to be between 2% 
and 8% crystalline, and between 17% and 24% crystalline, respectively 
(Figure 7). 
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Figure 7.  Percent crystallinity of insulin particles, as determined by the HPLC dissolution 
method described in the U.S. Pharmacopeia and National Formulary.  Each bar shows mean 
± S.D. of three experiments. 
 
2.2.6. Dissolution of Insulin Particles 
The concentration of insulin was measured over time in PBS solution to 
determine the dissolution rate of the different powders (Figure 8).  The 
unprocessed insulin follows Higuchi dissolution kinetics,104 and the 
nanoparticles and microparticles appear to show a burst dissolution 
phenomenon after 15 minutes.  The dissolved masses of nanoparticles and 
microparticles were both significantly different from the dissolved mass of 
unprocessed powder after 15 minutes (p = 0.0021 and p = 0.0054, 
respectively).  The dissolved masses of neither the nanoparticles nor the 
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microparticles were significantly different from the dissolved mass of the 
unprocessed insulin after 8 hours. 
 
Figure 8.  Dissolution of insulin powders over time.  Each value represents mean ± S.D. of 
three experiments. 
 
2.2.7. Bulk Powder tap Density 
The tap test method was used to determine the bulk density of the insulin 
powders before and after processing.  Density of the unprocessed insulin 
powder was determined to be 0.48 ± 0.08 mg/µL (Figure 3).  The nanoparticle 
bulk density was determined to be 0.28 ± 0.04 mg/µL, and the bulk density of 
the insulin microparticles was determined to be 0.063 ± 0.004 mg/µL.  
Analysis of variance revealed a p-value of 0.00025 (p < 0.05), indicating a 
statistically significant difference between the bulk densities of each group. 
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2.3. Discussion 
Pure insulin microparticles with sizes within the respirable range were 
produced from the solvent-induced agglomeration of insulin nanoparticles.  
Nanoparticles were produced using titration and were shown to have a strong 
correlation between pH and particle size (Figure 1).  Microparticles were then 
produced using ethanol to displace the aqueous solvent and induce 
nanoparticle agglomeration.  The proposed mechanism for this agglomeration 
is a combination of decreased electrostatic interactions between 
nanoparticles due to the addition of the organic phase, and the deposition of 
dissolved insulin onto the surface of the nanoparticles, forming microparticles 
with a leaf-like morphology.  Alternatively, it might be possible that the 
addition of the organic phase caused a partial dissolving of the nanoparticles, 
thereby causing their surfaces to fuse together. 
The sizes of the microparticles were independent of the size of the 
nanoparticles used, and had a mean aerodynamic diameter that was roughly 
between 0.42 µm and 4.3 µm.  This range of particle sizes is similar to other 
dry powder insulin formulations, such as Exubera (3.5 µm),96 and a 
formulation based on the Spiros technology (2-3 µm).105  Additionally, these 
particles were smaller than those produced using AIR technology (5-30 
µm).106  Based on Equation 1, our data suggest a mean shape factor equal to 
0.14 (assuming a ρref of 1 mg/µL and ρtap = ρparticle).  This value is much less 
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than 1, indicating that our particles are aspherical and highly irregular in 
morphology, thus making them good candidates for inhalation.  This 
observation is further corroborated by SEM imaging (Figure 2). 
 Circular dichroism was used to determine changes in the secondary 
structure of insulin that might occur as a result of particle processing.  The 
data suggest that there are no irreversible changes that occur as a result of 
processing, and that the thermal stability of the insulin processed into 
microparticles and nanoparticles is neither enhanced nor diminished (Figure 
5).  This suggests that the activity of the protein is retained throughout each 
step of the formulation. 
 The crystallinity of the insulin particles was first examined using 13C 
CP/MAS NMR (Figure 6).  Due to their highly ordered nature, crystalline 
materials will have relatively narrow lines in a 13C CP/MAS spectrum, while 
disordered or amorphous materials have relatively broad lines.  Insulin 
consists of 51 amino acids and therefore the spectrum will be quite 
complicated because every amino acid will have at least an amide and a 
carbon, each of which will have slightly different conformations and thus 
different chemical shifts.  Because of this, even the 13C CP/MAS spectrum of 
a crystalline protein will appear to have broad lines even though it may 
actually be composed of many narrow lines with slightly different chemical 
shifts.  Therefore, it would be expected that there would be very few 
differences between the 13C CP/MAS spectra of amorphous and crystalline 
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proteins, and any differences may be subtle.  The sharply resolved peaks of 
the unprocessed insulin would suggest that it is crystalline while all of the 
other samples appear to be amorphous, which is corroborated by the 
dissolution testing.  However, at this time nothing can be said about the purity 
of each form because there could be some crystalline insulin in the samples 
that appears to be amorphous. 
Crystallinity was also determined by dissolution testing, as defined by 
the 2005 U.S. Pharmacopoeia National Formulary, with modifications.  
Buffered acetone TS was used to dissolve the amorphous insulin from each 
sample, the concentration of which was then determined and used to 
estimate the crystallinity of the particles.  The unprocessed insulin was shown 
to be about 17 times more crystalline than the nanoparticles, and 4 times 
more crystalline than the microparticles (Figure 7).  The dissolution rate of 
both the microparticles and the nanoparticles exhibited a burst effect over the 
first few minutes when compared to the unprocessed insulin (Figure 8).  This 
burst may be due to the rapid dissolution of amorphous material deposited on 
the surface of the particles during processing or possibly during lyophilization.  
In the case of the nanoparticles, it is probable that the large total surface area 
of the particles also plays a significant role in increasing the dissolution rate.  
This may be beneficial in a pulmonary insulin formulation if the desired 
therapeutic effect is rapid control of spikes in glucose levels.  This type of 
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formulation may be adjusted for sustained control of glucose over long 
periods of time, or for postprandial glucose control. 
 One concern with the technique outlined in the U.S. Pharmacopoeia is 
that it is based on the assumption that amorphous materials dissolve more 
rapidly than crystalline materials.  This assumption might not always apply 
when using nanoparticles because of the enhanced dissolution velocity of 
particles at this scale, so interpretation of the results should be approached 
conservatively.29,107  Additionally, it would be prudent to examine the shelf-life 
of the formulation using an accelerated stability study.  Solid-state drug 
formulations are typically more thermodynamically stable in their crystalline 
forms than in their amorphous forms, which could cause the microparticle 
formulation to crystallize and possibly lose its burst-release properties over 
time.  Future studies should also include examination of the formulation 
performance in vivo to determine the relative performance of this formulation 
over intravenous and subcutaneous insulin formulations, as well as other 
pulmonary insulin formulations. 
 
2.4. Conclusions 
Pure insulin microparticles produced through agglomeration of insulin 
nanoparticles may be a potential candidate for a pulmonary insulin 
formulation.  The lack of penetration enhancers and other excipients in this 
formulation may reduce the occurrence of unforeseen side effects, thus 
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making it potentially safer than existing alternatives.  Additionally, the 
processing steps necessary for this formulation are minimal and did not 
denature or degrade the peptide, which may be a concern with currently used 
techniques.  A major benefit of this formulation method is the ability to 
produce pure insulin microparticles, which has not been demonstrated with 
techniques such as spray drying.  The development of a dry powder insulin 
formulation for the treatment of diabetes may help to reduce, or altogether 
eliminate, patient dependence on painful injections, and thus may help to 
increase patient compliance. 
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